<!DOCTYPE html>
<html lang="en-US"><head>
		<meta charset="UTF-8">
		<title>FR940627-2-00086</title>
	</head>
	<body>
		<main>
			<p><!-- PJG STAG 4703 -->  <!-- PJG ITAG l=69 g=1 f=1 -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=55 g=1 f=1 -->  <DOCTITLE>Opportunity For Licensing: Transforming Growth Factor_Beta </DOCTITLE> <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <AGENCY> <!-- PJG ITAG l=10 g=1 f=2 --> AGENCY: <!-- PJG /ITAG -->  <!-- PJG ITAG l=10 g=1 f=1 -->  National Institutes of Health, Public Health Service, DHHS. <!-- PJG /ITAG -->  <!-- PJG QTAG 02 --> <!-- PJG /QTAG -->   <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline --> </AGENCY> <ACTION> <!-- PJG ITAG l=10 g=1 f=2 --> ACTION: <!-- PJG /ITAG -->  <!-- PJG ITAG l=10 g=1 f=1 -->  Notice. <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=59 g=1 f=1 -->  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG --> </ACTION> <SUMMARY> <!-- PJG ITAG l=10 g=1 f=2 --> SUMMARY: <!-- PJG /ITAG -->  <!-- PJG ITAG l=10 g=1 f=1 -->  The National Institutes of Health (NIH), Department of Health and Human Services (DHHS), seeks licensee(s) who can effectively pursue the preclinical, clinical and commercial development of transforming growth factor_beta (TGF-beta). In an earlier notice ( <!-- PJG /ITAG -->  <!-- PJG ITAG l=10 g=1 f=4 --> Federal Register <!-- PJG /ITAG -->  <!-- PJG ITAG l=10 g=1 f=1 -->  Vol. 58, No. 166 pages 45494&hyph;5, August 30, 1993) NIH had announced that several fields of use for TGF-beta were available for licensing. Since this time, two additional fields of use have become available for non-exclusive licensing: 1) the nonsystemic administration of TGF-beta for repair of soft tissue; and 2) the systemic administration of TGF-beta for treatment or prevention of vascular ischemia and/or reperfusion injury. The following patents and patent applications covering TGF-beta are available to be licensed: U.S. Patent 5,104,977 entitled ``Purified Transforming Growth Factor Beta,'' U.S. patent application 08/048,956 entitled ``Promotion of Cell Proliferation by Use of Transforming Growth Factor Beta,'' and foreign counterpart applications claiming priority from U.S. patent applications 06/468,590 and 06/500,833 both entitled ``Repair of Tissue in Animals.'' The patent rights in these inventions have been assigned to the United States of America. <!-- PJG /ITAG -->  <!-- PJG QTAG 02 --> <!-- PJG /QTAG -->   <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline --> </SUMMARY> <SUPPLEM> <!-- PJG ITAG l=10 g=1 f=2 --> SUPPLEMENTARY INFORMATION: <!-- PJG /ITAG -->  <!-- PJG ITAG l=10 g=1 f=1 -->  The NIH seeks licensee(s), who in accordance with requirements and regulations governing the licensing of government-owned inventions (37 CFR part 404), have the most meritorious plan for the development of TGF-beta to a marketable status to meet the needs of the public and with the best terms for the NIH. The criteria that NIH will use to evaluate license applications will include, but not be limited to those set forth by 37 CFR 404.7(a)(1)(ii)&hyph;(iv). <!-- PJG /ITAG -->  <!-- PJG QTAG 02 --> <!-- PJG /QTAG -->   <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline --> </SUPPLEM> <ADDRESS> <!-- PJG ITAG l=10 g=1 f=2 --> ADDRESSES: <!-- PJG /ITAG -->  <!-- PJG ITAG l=10 g=1 f=1 -->  Requests for a copy of the patent applications, license application form, or other questions and comments concerning the licensing of this technology should be directed to: Mark D. Hankins, Technology Licensing Specialist, Office of Technology Transfer, National Institutes of Health, 6011 Executive Boulevard, Suite 325, Rockville, MD 20852&hyph;3804. Telephone: (301) 496&hyph;7735 ext. 265; Facsimile: (301) 402&hyph;0220. A signed confidentiality agreement will be required to receive copies of the patent applications. <!-- PJG /ITAG -->  <!-- PJG QTAG 04 --> <!-- PJG /QTAG -->   <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline -->  <!-- PJG ITAG l=21 g=1 f=1 --> Dated: June 15, 1994.  <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG --> </ADDRESS> <SIGNER> <!-- PJG ITAG l=06 g=1 f=1 --> Barbara M. McGarey, J.D., <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG --> </SIGNER> <SIGNJOB> <!-- PJG ITAG l=04 g=1 f=1 --> Deputy Director, Office of Technology Transfer.  <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG --> </SIGNJOB> <FRFILING> <!-- PJG ITAG l=40 g=1 f=1 --> [FR Doc. 94&hyph;15469 Filed 6&hyph;24&hyph;94; 8:45 am]  <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG --> </FRFILING> <BILLING> <!-- PJG ITAG l=68 g=1 f=1 --> BILLING CODE 4140&hyph;01&hyph;P  <!-- PJG /ITAG --> </BILLING>  <!-- PJG /STAG --></p>
		</main>
</body></html>
            